Top Tweets for #Rilonacept
Ma et al found using spatial #transcriptomics & #proteomics, how the anti-inflammatory medication #rilonacept reshaped the cardiac immune environment in a patient with lymphocytic #myocarditis. Learn about a promising treatment https://t.co/z9DrxACVoW
@annevillanueva
#EHJCVI 🔥🔥Does clinical response to prolonged #rilonacept treatment for active #pericarditis_recurrences correlate with improvement on #whyCMR? Check a #RHAPSODY_subgroup_analysis by Paul C Cremer et al here 👉 https://t.co/J8EKNqnHkI @ESC_Journals @bernhard_gerber
The chances of $CRDL taking over large part of $KNSA market share are high, where the drug price will be much lower & the safety will have a crucial advantage in young adults that prefer to stay away from an "Immunosuppressive drug" like #Rilonacept or #Arcalyst
Also with $KNSA faces challenges in penetrating the market for 1st recurrence patients, with only 15% of these patients, while $CRDL can be 1st in line for 1st recurrence!
Looks like $KNSA should be worried & starts thinking to buy-out $CRDL before they take their rilonacept potential
$CRDL's CEO said, expanding the market opportunity with MAVERIC-2 into new patients population & provides a path for an accelerated regulatory approval timeline.
Indeed, this new $CRDL's study can get FDA accelerated approval if it's successfuly help the growing number of recurrent #pericarditis patients who are looking for alternative options to chronic use of immunosuppressant drug like #rilonacept!
Imagine a young man/woman who have to use immunusuppressive drug for years & the risk of going out to parties or even restaurants & get infected with another virus due to their lower immune system!!!
According to $CRDL's CEO, expanding the market opp
“MAVERIC-2 provides an exciting opportunity to expand the market potential for CardiolRx through the execution of a cost-effective study and potentially provides a path for an accelerated regulatory approval timeline,”
$CRDL is bouncing back, but still has a a lot of upside from here!
The upside will starts soon, especially when the street will realize that CardiolRx actually successfully reduced pain & CRP during the 8-weeks treatment the same as the strong immunosuppresive drug #rilonacept as showed in their Ph-3 RHAPSODY trial with 86 patients!!!
So, $CRDL has the proof of concept in its pilot trial & will continue with 24 out of 27 (very positive point that 89% of the patient continue into the expansion period- they must felt the good effect of the drug) into expansion-period for another 18 weeks.
On the safety side, the study showed a safe & well tolerable drug, but we can rely on a similar drug as $GWPH's drug #Epidiolex that was approved for treatment of epilepsy by the FDA in 2018 & treating KIDS with epilepsy, so it is sure safe for adult patients with #Pericardits & next is the #Myocarditis as well!
The same comparison I did with #rilonacept Ph2 & $CRDL's Ph2 pilot study..
Now it's vs. rilonacept CRP& NRS Ph-3 data from "The new England journal of medicine"
Again $CRDL's baseline (BL) is higher 5.71 vs rilonacept Ph3 with 3.70 (pink highlighted)
CRP
$CRDL 8wks difference -5.39
Rilonacept 6wks difference -3.48
Negative value indicates an improvement in CRP
Pain using NRS
$CRDL 8wks difference -3.7 (high BL 5.8)
Rilonacept 8wks (n=82) -3.9 (lower BL 4.5)
Agree 100% & id we check the base-line, $CRDL's enrolled patients with higher BL than #rilonacept & still got amazing reduction in pain using NRS
@Gantosj A pain scale of 2 would be low level tolerable pain that many people live with.
Reporting 5 would be treated with pain relief of sorts.
2 ok 5 a concern. 10 is upper limit I have never seen reported outside an ER.
The same comparison I did with #rilonacept Ph2 & $CRDL's Ph2 pilot study..
Now it's vs. rilonacept CRP& NRS Ph-3 data from "The new England journal of medicine"
Again $CRDL's baseline (BL) is higher 5.71 vs rilonacept Ph3 with 3.70 (pink highlighted)
CRP
$CRDL 8wks difference -5.39
Rilonacept 6wks difference -3.48
Negative value indicates an improvement in CRP
Pain using NRS
$CRDL 8wks difference -3.7 (high BL 5.8)
Rilonacept 8wks (n=82) -3.9 (lower BL 4.5)
1/5 ... The best way to compare $CRDL's data vs rilonacept is side by side
Rilonacept NRS Pain Score in Ph2 Pilot Trial showing that ONLY 9 patients had NRS data at EoTP
Their baseline (BL) was way lower 4.5 vs $CRDL's BL 5.8
Mean difference -3.8 vs $CRDL's -3.7 (still with higher BL)
So, $CRDL's data looks very promising & next step would be meeting the FDA & get clearance to start Ph3
Pericardial late gadolinium enhancement and recurrence: a substudy from #RHAPSODY, a phase 3 clinical trial of #rilonacept in #recurrent #pericarditis @AbbateAntonio @ImazioMassimo @AllanLKleinMD1 @PaulCremerMD @MarcoDelBuono3 @NicolaPotereMD @kiniksa
https://t.co/DpDgtNuYa7
#Rilonacept (Arcalyst) Pediatrics Dosing & Monitoring for #Pericarditis
#pedsTwitter #RheumTwitter #MedTwitter #CardioTwitter #PharmaTwitter #biotech
#PedsInCrisis @Regeneron #pedsICU
Come visit Kiniksa Pharmaceuticals virtual posters at @ACRheum Scientific Sessions. #ACR21 #recurrentpericarditis #rilonacept #heart #kiniksa https://t.co/9jSQXaF6Jf
Come visit Kiniksa Pharmaceuticals virtual posters at @ACRheum Scientific Sessions. #ACR21 #recurrentpericarditis #rilonacept #heart #kiniksa https://t.co/9jSQXaF6Jf
The U.S @FDA has approved a new drug called #rilonacept (Arcalyst) to specifically treat recurrent #pericarditis, a painful inflammation of the fluid-filled sac that surrounds the heart
With expanded approval of #rilonacept for recurrent #pericarditis, find the evidence in DynaMed: https://t.co/XWcbhzC2Mw #CardioTwitter
FDA approves #rilonacept to treat recurrent pericarditis and reduce the risk of recurrence.
https://t.co/Xr6N4hovPW
ICYMI: The @US_FDA announced it approved #rilonacept injection to treat and reduce risk for recurrent #pericarditis in adults and children 12 years and older #CardioTwitter https://t.co/yOOWlzcv8G
The #FDA has approved #rilonacept (ARCALYST) for recurrent #pericarditis in adults and older children.
https://t.co/7vSRnGnPU0
ICYMI: “These data could represent a paradigm shift, in that #rilonacept... potentially obviated the need for initiation of steroids in patients experiencing recurrence despite colchicine” #AHA20 #cardiotwitter @_brendan_ @AllanLKleinMD1 @ClevelandClinic https://t.co/xkGcHQmzDb
In patients with recurrent pericarditis, compared with placebo, #rilonacept better resolved recurrent episodes and lowered risk for future episodes #AHA20 @AHAMeetings @heartnews @american_heart #cardiotwitter @_brendan_ @AllanLKleinMD1 @ClevelandClinic https://t.co/xkGcHQ4YLD
#AHA20 @AHAMeetings
#RHAPSODY trial
#Rilonacept (IL-1α/IL-1β trap) provided rapid& sustained reductions in pain & CRP soon after 1st dose in recurrent pericarditis
Rilonacept monotherapy reduced RP event risk by 96% vs placebo
❓Targeted therapeutic option for patients with RP
We are pleased to announce we have received Orphan Drug Designation from the U.S. FDA for #Rilonacept, our investigational therapy for the treatment of #Pericarditis https://t.co/0BDYUabAnc
Last Seen Hashtags on Sotwe
Trends for you
Most Popular Users
Elon Musk 
@elonmusk
241.2M followers
Barack Obama
@barackobama
119.1M followers
Cristiano Ronaldo
@cristiano
112.8M followers
Donald J. Trump
@realdonaldtrump
111.8M followers
Narendra Modi
@narendramodi
107.1M followers
Rihanna
@rihanna
98.3M followers
NASA
@nasa
92.3M followers
Justin Bieber
@justinbieber
91.5M followers
KATY PERRY
@katyperry
89M followers
Taylor Swift
@taylorswift13
82.9M followers
Lady Gaga
@ladygaga
74.4M followers
Virat Kohli
@imvkohli
71.9M followers
Kim Kardashian
@kimkardashian
70.4M followers
YouTube
@youtube
68.8M followers
Neymar Jr
@neymarjr
64.8M followers
Bill Gates
@billgates
64.6M followers
The Ellen Show
@theellenshow
62.4M followers
Selena Gomez
@selenagomez
62.1M followers
CNN
@cnn
61.8M followers
X
@x
60.8M followers